SCHEMBL30615224

SCHEMBL30615224

CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(O)cc3oc2=O)c1F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 14/20 0.74
RAF1 P04049 13/20 0.74
CYP2C9 P11712 2/20 0.74
BRAF P15056 1/20 0.74
MAP2K2 P36507 1/20 0.74
MAP2K5 Q13163 1/20 0.74
CYP3A4 P08684 1/20 0.58
HSD17B3 P37058 3/20 0.49
KDM4E B2RXH2 2/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ERAP1 Q9NZ08 1/20 0.49
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613689 1.00 MAP2K1 (0.74) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL29358292 0.85 MAP2K1 (1.00) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL29360048 0.85 MAP2K1 (1.00) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL960093 0.85 MAP2K1 (1.00) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL29515377 0.85 MAP2K1 (1.00) MAP2K1RAF1CYP2C9BRAFMAP2K2
SCHEMBL15901486 0.85 RAF1 (0.54) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL959675 0.84 MAP2K1 (0.98) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL959677 0.84 MAP2K1 (0.98) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL963841 0.84 MAP2K1 (0.98) MAP2K1RAF1CYP2C9BRAFMAP2K2
Avutometinib SCHEMBL963844 0.84 MAP2K1 (0.98) MAP2K1RAF1CYP2C9BRAFMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4701735-A1 HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR Nested Therapeutics, Inc. (US) 2026-03-04 EP disclosed
EP-4514471-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-03-05 EP disclosed
CN-119487021-A Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) 内斯特治疗公司 2025-02-18 CN disclosed
WO-2024226579-A9 HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR NESTED THERAPEUTICS, INC. (US) 2024-12-26 WO disclosed
WO-2024226579-A1 HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR NESTED THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
WO-2023211812-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed